JAK Inhibitors: Monitoring Infection and Thrombosis Risks

You’ve been prescribed a JAK inhibitor is a class of oral medications that block specific immune pathways to reduce inflammation in conditions like rheumatoid arthritis and psoriasis. These drugs are powerful. They work fast. But they come with serious warnings that you cannot ignore. The FDA and European Medicines Agency have issued black box warnings for these drugs because they can increase your risk of blood clots and severe infections. If you are starting or considering this treatment, understanding exactly what to monitor is not just good practice-it’s essential for your safety.

This isn’t about scaring you away from effective treatment. It’s about empowering you with the facts so you can take control of your health alongside your doctor. We will break down the specific risks of thrombosis (blood clots) and infections, how different JAK inhibitors compare, and the exact steps you need to take to stay safe.

Understanding the Blood Clot Danger

The most critical safety concern with JAK inhibitors is venous thromboembolism (VTE). This term covers two life-threatening conditions: deep vein thrombosis (DVT), where a clot forms in a deep vein usually in the leg, and pulmonary embolism (PE), where that clot travels to the lungs.

Why does this happen? JAK inhibitors work by blocking Janus kinase enzymes. While this stops inflammation, it also interferes with signals that regulate platelets and red blood cells. Specifically, inhibiting JAK2 affects thrombopoietin signaling, which can alter how your blood clots. A massive analysis published in Nature Scientific Reports in 2022 looked at nearly 127,000 patients. It found that people taking JAK inhibitors had a 2.37 times higher reporting odds ratio for thromboembolic events compared to those on other drugs. For pulmonary embolism specifically, the risk was nearly three times higher.

Not all JAK inhibitors are created equal when it comes to this risk. Older drugs like tofacitinib (Xeljanz) inhibit multiple JAK enzymes (JAK1, JAK2, JAK3). Newer agents like upadacitinib (Rinvoq) and filgotinib (Jyseleca) are designed to be more selective, targeting primarily JAK1. Early data suggests this selectivity might lower the clotting risk. For instance, recent trial data presented at the American College of Rheumatology conference showed upadacitinib had fewer VTE events per 100 patient-years than tofacitinib in patients without traditional risk factors. However, regulators warn that the risk applies to the entire class, and you should never assume one drug is "safe" from clots just because it’s newer.

Who Is at Highest Risk?

Your personal risk profile dictates whether a JAK inhibitor is right for you. The EMA and FDA have tightened restrictions significantly since 2021. You are considered high-risk if you fall into any of these categories:

• Age 65 or older: The risk of VTE jumps dramatically in this group. One study found the risk ratio for VTE was 3.81 for patients aged 65+.
• History of Blood Clots: If you’ve had a DVT or PE before, your risk increases by more than five times.
• Cardiovascular Risk Factors: This includes current or former smoking, high blood pressure, high cholesterol, or diabetes.
• Obesity: A BMI of 30 or higher is a significant independent risk factor.
• Immobility: Recent surgery, long flights, or bed rest compound the danger.

If you have multiple risk factors, guidelines strongly suggest avoiding JAK inhibitors altogether unless no other treatment options exist. The European Medicines Agency now recommends these drugs as second-line therapy, meaning you should try TNF inhibitors (biologics) first unless there’s a compelling reason not to.

Managing Infection Risks

While blood clots get the headlines, infections are actually the most common serious adverse event reported with JAK inhibitors. Because these drugs suppress the immune system’s ability to fight invaders, you become more vulnerable to bacteria, viruses, and fungi.

Data from the FDA’s adverse event database shows that serious infections account for nearly one-third of all reported safety issues with these drugs. The most frequent culprit is herpes zoster (shingles). In fact, shingles makes up over 14% of all infection reports. Other common threats include pneumonia, urinary tract infections, and reactivation of latent tuberculosis.

Here is what you need to do before you ever take your first pill:

1. Update Vaccinations: You must receive the shingles vaccine (Shingrix), pneumococcal vaccine, and flu shot at least four weeks before starting treatment. Live vaccines are strictly prohibited while on JAK inhibitors.
2. Screen for Tuberculosis: Your doctor will likely order a TB test (PPD skin test or IGRA blood test) to ensure you don’t have latent TB, which could reactivate.
3. Check for Active Infections: Do not start therapy if you have an active cold, flu, or bacterial infection. Wait until it resolves completely.

Once you are on the medication, stay alert. Fever, chills, persistent cough, or painful skin rashes are not things to "wait out." Contact your doctor immediately. Real-world patient stories highlight this urgency; many users report hospitalizations due to shingles or pneumonia that were caught too late because they dismissed early symptoms as minor.

Comparing JAK Inhibitors: Safety Profiles

Choosing between available options requires looking at their specific mechanisms and safety data. Here is how the major players stack up:

Note that while upadacitinib and filgotinib show promise regarding lower clotting risks, they are not risk-free. The absolute risk difference might seem small in statistics (e.g., 0.7% vs 0.4%), but for an individual, that difference is everything. Always discuss your specific medical history with your rheumatologist to choose the safest option for you.

Essential Monitoring Checklist

You cannot set and forget this medication. Active monitoring is part of the treatment plan. Here is your checklist for staying safe:

• Lipid Panel: JAK inhibitors raise cholesterol levels. Expect total cholesterol to rise by 15-20% and LDL by 10-15% within the first month. Get tested at 4 weeks and 12 weeks. Statins may be needed.
• Complete Blood Count (CBC): Check every 4-8 weeks initially. Look for drops in white blood cells (neutropenia) or hemoglobin (anemia), which increase infection and fatigue risks.
• Leg Symptoms: Know the signs of DVT: swelling in one leg, pain, warmth, or redness. If you experience these, seek emergency care immediately.
• Chest Pain & Shortness of Breath: These are signs of PE or heart issues. Do not drive yourself to the hospital; call emergency services.
• Skin Changes: Watch for blisters (shingles) or unusual moles (skin cancer risk is also elevated).

When to Stop or Switch

There are clear scenarios where continuing a JAK inhibitor is dangerous. The American College of Rheumatology guidelines state that you must stop the drug immediately if:

• A blood clot is confirmed.
• You develop a serious active infection (like pneumonia or sepsis).
• You experience major adverse cardiovascular events (heart attack or stroke).

If you stop due to infection, you can sometimes restart once the infection is fully resolved, but this decision must be made by your specialist. If you stop due to a blood clot, switching to another JAK inhibitor is generally not recommended. Your doctor will likely switch you to a biologic agent like a TNF inhibitor or IL-6 inhibitor, which have different safety profiles.

Next Steps for Patients

If you are currently on a JAK inhibitor, review your risk factors with your doctor today. Ask them: "Is my current dose appropriate given my age and health history?" If you are considering starting one, demand a thorough pre-screening. Do not accept a prescription without a discussion of alternatives like biologics, especially if you smoke or are over 65.

Stay informed. Join patient support groups where real experiences are shared. While anecdotes aren’t scientific proof, they provide valuable insights into day-to-day management. Finally, keep a symptom diary. Tracking minor changes in energy, mood, or physical sensation can help catch complications early, turning potential emergencies into manageable adjustments.